News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Jiangsu Hengrui Medicine Co. Ltd. In-Licenses China Rights to AMD mAb From X-BODY BioSciences, Inc.



4/5/2013 11:56:18 AM

by Richard Daverman, PhD

April 5, 2013 -- Jiangsu Hengrui Medicine has in-licensed China rights to a novel antibody from X-Body Biosciences of Waltham, MA. Hengrui made an unspecified upfront payment, though the companies said the contract was a “multi-million dollar” agreement. The antibody program was generated by X-Body’s platform for Age-related Macular Degeneration (AMD). More details....

Stock Symbol: (SHA: 600276)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES